A novel therapeutic modality of inhibiting the glyco-immune checkpoint axis to treat cancer

被引：3
|
作者：
Cao, Lizhi [1 ]
Petrone, Adam [1 ]
Gatlin, Wayne [1 ]
Che, Jenny [1 ]
Das, Abhishek [1 ]
LeBlanc, Robert [1 ]
Siddiquee, Zakir [1 ]
Nerle, Sujata [1 ]
Stanczak, Michal [2 ]
Mayo, Michele [1 ]
Xu, Lihui [1 ]
Normington, Karl [1 ]
Brown, Jeff [1 ]
Yao, Wei [1 ]
Bertozzi, Carolyn [3 ]
Broderick, James [1 ]
Laubli, Heinz [2 ]
Peng, Li [1 ]
机构：
[1] Palleon Pharmaceut, Waltham, MA USA
[2] Univ Basel Hosp, Dept Biomed, Canc Immunol Lab, Basel, Switzerland
[3] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-LB-109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-109
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Targeting siglec-7/9 glyco-immune checkpoints in prostate cancer for enhanced immune responses and tumor suppression
    Wen, Ru
    Marti, G. Edward
    Stark, Jessica
    Marques, Fernando Jose Garcia
    Riley, Nick
    Bermudez, Abel
    Zhao, Hongjuan
    Bertozzi, Carolyn
    Pitteri, Sharon
    Brooks, James
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Siglec-15/sialic acid axis as a central glyco- immune checkpoint in breast cancer bone metastasis
    Wang, Yixian
    Xu, Zhan
    Yu, Liqun
    Wang, Chenhang
    Ding, Haoxue
    Gao, Yang
    Sun, Han
    Xia, Meng
    Chen, Yuda
    Wu, Kuan- Lin
    Wu, Yi-Hsuan
    Xiao, Han
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (05)
  • [23] Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer
    He, Li-Hong
    Zhang, Xiao-Zhen
    Lao, Meng-Yi
    Zhang, Han-Jia
    Yang, Han-Shen
    Bai, Xue-Li
    CANCERS, 2023, 15 (08)
  • [24] Laser immunotherapy: Novel modality to treat cancer through specific antitumor immune response
    Li X.
    Chen Wei R. W.R.
    Zhongguo Jiguang/Chinese Journal of Lasers, 2010, 37 (11): : 2698 - 2702
  • [25] Laser Immunotherapy:Novel Modality to Treat Cancer through Specific Antitumor Immune Response
    李晓松
    陈伟
    中国激光, 2010, 37 (11) : 2698 - 2702
  • [26] Therapeutic modality, antitumor efficacy and immune safety for targeting innate immune checkpoint TREX1 as cancer immunotherapy
    Xing, Cong
    Tu, Xintao
    Huai, Wanwan
    Tang, Zhen
    Song, Kun
    Knox, Kennady
    Dobbs, Nicole
    Yang, Kun
    Yan, Nan
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [27] Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
    Stamm, Hauke
    Wellbrock, Jasmin
    Fiedler, Walter
    MAMMALIAN GENOME, 2018, 29 (11-12) : 694 - 702
  • [28] Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
    Hauke Stamm
    Jasmin Wellbrock
    Walter Fiedler
    Mammalian Genome, 2018, 29 : 694 - 702
  • [29] The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
    Krishnamoorthy, Vignesh
    Daly, John
    Kim, Jimmy
    Piatnitca, Lidia
    Yuen, Katie A.
    Kumar, Bhoj
    Ghahfarrokhi, Mehrnoush Taherzadeh
    Bui, Tom Q. T.
    Azadi, Parastoo
    Vu, Ly P.
    Wisnovsky, Simon
    LEUKEMIA, 2025, 39 (02) : 346 - 359
  • [30] To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
    De Keukeleire, Stijn
    Vermassen, Tijl
    De Schoenmakere, Gert
    Kruse, Vibeke
    Vermaelen, Karim
    Rottey, Sylvie
    ACTA CLINICA BELGICA, 2020, 75 (06) : 434 - 441
12345